Chiesi Farmaceutici S.p.A.

The US Food and Drug Administration is planning to transition away from the hydrofluoroalkane (HFA) propellants currently used in metered dose inhalers and is eager to avoid many of the complexities t

AbbVie is paying $1.4bn in cash for privately held Aliada Therapeutics and its sole clinical candidate – but if ALIA-1758 proves to be a best-in-class disease-modifying therapy for Alzheimer’s disease

During the course of conducting interviews, attending conferences and providing other coverage across the region, Scrip ‘s on-the-ground team in APAC often hears comments and views that are worth hig

Chiesi Farmaceutici S.p.A. is actively expanding its rare disease business in Japan through a subsidiary established there in 2022 and as part of the family-owned Italian firm's global push into this